Key terms

About ADMA

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ADMA news

Apr 02 5:32pm ET Kaitlin Kestenberg Promoted to COO at ADMA Biologics Mar 26 6:17am ET ADMA Biologics Poised for Robust Growth: Buy Rating Affirmed with Enhanced Price Target Mar 11 7:19am ET ADMA Biologics announces FDA approval of sBLAs for ASCENIV, BIVIGAM Mar 01 7:28am ET ADMA Biologics price target raised to $10 from $9 at Mizuho Feb 29 6:43am ET Buy Rating Affirmed for ADMA Biologics Amidst Strong Financial Growth and Positive Long-Term Outlook Feb 28 4:44pm ET ADMA Biologics Enhances Executive Compensation and Seeks New CFO Feb 28 4:35pm ET ADMA Biologics CFO Brian Lenz to transition out of role Feb 28 4:31pm ET ADMA Biologics ups FY24 revenue view to over $330M from $320M, consensus $315.3M Feb 28 4:29pm ET ADMA Biologics reports Q4 EPS (8c), consensus 2c Feb 21 8:14am ET ADMA Biologics Launches ADMAlytics AI Program Feb 21 7:14am ET ADMA Biologics successfully implements ADMAlytics Jan 25 11:38am ET Biotech Alert: Searches spiking for these stocks today Jan 25 11:38am ET Biotech Alert: Searches spiking for these stocks today Jan 24 11:08am ET Biotech Alert: Searches spiking for these stocks today Jan 09 6:18am ET ADMA Biologics price target raised to $6 from $5 at H.C. Wainwright Jan 08 7:12am ET ADMA Biologics increases FY24-FY25 revenue outlook to $320M-$370M Jan 08 7:10am ET ADMA Biologics reports preliminary FY23 revenue $256M-$258M, consensus $252.79M Jan 08 7:10am ET ADMA Biologics reports preliminary Q4 revenue $72M-$74M, consensus $68.49M

No recent news articles are available for ADMA

No recent press releases are available for ADMA

ADMA Financials

1-year income & revenue

Key terms

ADMA Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ADMA Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms